Beta Fulltext view is in preview — article structure may vary. Browse all articles
Contents
Diabetes & Obesity International Journal Research Article 7 min read

Recent Technological and Pharmacological Advances in Type 1 Diabetes

Nitesh D Kuhadiya*
* Corresponding author
ISSN: 2574-7770  10.23880/doij-16000122  Received: August 23, 2016  Published: August 31, 2016
 — views
 50 references
PDF
Keywords
Type 1 Diabetes GLP-1 agents SGLT-2 Inhibitors Glucagon Triple Therapy Ketosis Diabetic Ketoacidosis (DKA) Continuous Glucose Monitoring (CGM) Insulin pump Closed Loop System
Abstract

A vast majority of patients with type1 diabetes (T1D) are not at the glycemic goal of an HbA1c of less than 7%. It continues to remain a very tough disease and the patients often get very frustrated while managing the unpredictable fluctuations of blood glucose coupled with emotional volatility.

References

  1. Varanasi A, Bellini N, Rawal D, Vora M, Makdissi A, et al. (2011) Liraglutide as additional treatment for type 1 diabetes. Eur J Endocrinol 165(1): 77-84.
  2. Kuhadiya ND, Malik R, Bellini NJ, Patterson JL, Traina A, et al. (2013) Liraglutide as additional treatment to insulin in obese patients with type 1 diabetes mellitus. Endocr Pract 19(6): 963-967.
  3. Kuhadiya ND, Dhindsa S, Ghanim H, Mehta A, Makdissi A, et al. (2016) Addition of Liraglutide to Insulin in Patients with Type 1 Diabetes: A Randomized Placebo-Controlled Clinical Trial of 12 Weeks. Diabetes care 39(6): 1027-1035.
  4. Lind M, Svensson AM, Kosiborod M, Gudbjornsdottir S, Pivodic A, et al. (2014) Glycemic control and excess mortality in type 1 diabetes. The New England journal of medicine 371(21): 1972-1982.
  5. (2016) Mortality in Type 1 Diabetes in the DCCT/EDIC Versus the General Population. Diabetes care 39(8): 1378-1383.
  6. (2001) Influence of intensive diabetes treatment on body weight and composition of adults with type 1 diabetes in the Diabetes Control and Complications Trial. Diabetes care 24(10): 1711-1721.
  7. Banting FG , CH Best (1922) Internal secretion of pancreas. Journal of Laboratory and Clinical Medicine 7(5): 465-480.
  8. Hahr AJ, Molitch ME (2008) Optimizing insulin therapy in patients with type 1 and type 2 diabetes mellitus: optimal dosing and timing in the outpatient setting. Am J Ther 15(6): 543-550.
  9. Zijlstra E, Demissie M, Graungaard T, Heise T, Nosek L, et al. (2016) Compatibility and Safety of Faster- Acting Insulin Aspart used in Continuous Subcutaneous Insulin Infusion Therapy in Patients with Type 1 Diabetes. Novel Treatment for Diabetes (posters). FRI-697.
  10. Novo Nordisk completes phase 3a trials comparing faster-acting insulin as part with NovoRapid® in people with type 1 and type 2 diabetes.
  11. Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study G, Tamborlane WV, Beck RW, Bode BW, Buckingham B, et al. (2008) Continuous glucose monitoring and intensive treatment of type 1 diabetes. The New England journal of medicine 359(14): 1464-1476.
  12. (2016) FDA Panel Votes to Allow Patients to Use CGM to Make Treatment Decisions.
  13. (2016) Mini Med 630 G system.
  14. Animas Vibe Brings Dexcom CGM Onto the Pump Screen.
  15. FDA Approves Tandem t: slim G4, Bringing CGM to the Touch screen Pump.
  16. Abbott’s FreeStyle Libre – Transforming Glucose Monitoring Through Utter Simplicity, Fingersticks Aside!
  17. Introducing the iLet. At long last, a fully integrated bionic pancreas. Carry your glucose metabolism in your pocket.
  18. Thabit H, Lubina-Solomon A, Stadler M, Leelarathna L, Walkinshaw E, et al. (2014) Home use of closed-loop insulin delivery for overnight glucose control in adults with type 1 diabetes: a 4-week, multicentre, randomised crossover study. The Lancet Diabetes & Endocrinology 2(9): 701-709.
  19. Bae JP, Lage MJ, Mo D, Nelson DR, Hoogwerf BJ (2016) Obesity and glycemic control in patients with diabetes mellitus: Analysis of physician electronic health records in the US from 2009-2011. J Diabetes Complications 30(2): 212-220.
  20. Whitehouse F, Kruger DF, Fineman M, Shen L, Ruggles JA, et al. (2002) A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes. Diabetes care 25(4): 724-730.
  21. Edelman S, Garg S, Frias J, Maggs D, Wang Y, et al. (2006) A double-blind, placebo-controlled trial assessing pramlintide treatment in the setting of intensive insulin therapy in type 1 diabetes. Diabetes care 29(10): 2189-2195.
  22. Ratner R, Whitehouse F, Fineman MS, Strobel S, Shen L, et al. (2005) Adjunctive therapy with pramlintide lowers HbA1c without concomitant weight gain and increased risk of severe hypoglycemia in patients with type 1 diabetes approaching glycemic targets. Exp Clin Endocrinol Diabetes 113(4): 199-204.
  23. Vella S, Buetow L, Royle P, Livingstone S, Colhoun HM, et al. (2010) The use of metformin in type 1 diabetes: a systematic review of efficacy. Diabetologia 53(5): 809-820.
  24. Harrison LB, Mora PF, Clark GO, Lingvay I (2013) Type 1 diabetes treatment beyond insulin: role of GLP-1 analogs. J Investig Med 61(1): 40-44.
  25. Kielgast U, Krarup T, Holst JJ, Madsbad S (2011) Four weeks of treatment with liraglutide reduces insulin dose without loss of glycemic control in type 1 diabetic patients with and without residual beta-cell function. Diabetes care 34(7): 1463-1468.
  26. Sarkar G, Alattar M, Brown RJ, Quon MJ, Harlan DM, et al. (2014) Exenatide treatment for 6 months improves insulin sensitivity in adults with type 1 diabetes. Diabetes care 37(3): 666-670.
  27. Traina AN, Lull ME, Hui AC, Zahorian TM, Lyons- Patterson J (2014) Once-weekly exenatide as adjunct treatment of type 1 diabetes mellitus in patients receiving continuous subcutaneous insulin infusion therapy. Can J Diabetes 38(4): 269-272.
  28. Dandona P, Kuhadiya ND, Ghanim H, Chaudhuri A (2016) Adjunct Therapies in Type 1 Diabetes. Endocr Pract 22(2): 277-280.
  29. Crisci I, Aragona M, Politi KS, Daniele G, Del Prato S (2015) GLP-1 receptor agonists in type 1 diabetes: a proof-of-concept approach. Acta Diabetol 52(6): 1129-1133.
  30. Curtis L, Holt H, Richardson T, Knott J, Partridge H (2016) GLP-1 analogue use in patients with sub- optimally controlled type 1 diabetes or obesity improves weight and HbA1c. Practical Diabetes 33(1): 13-17.
  31. Dejgaard TFFC, Knop FK, Tarnow L, Hansen TS, Almdal TP, et al. (2015) Efficacy and safety of liraglutide added to insulin therapy in patients with type 1 diabetes: the Lira-1 study. EASD Meeting.
  32. Dejgaard TF, Frandsen CS, Hansen TS, Almdal T, Urhammer S, et al. (2015) Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial. The lancet Diabetes & endocrinology 4(3): 221-232.
  33. Pieber TR, Deller S, Korsatko S, Jensen L, Christiansen E, et al. (2015) Counter-regulatory hormone responses to hypoglycaemia in people with type 1 diabetes after 4 weeks of treatment with liraglutide adjunct to insulin: a randomized, placebo-controlled, double-blind, crossover trial. Diabetes Obes Metab 17(8): 742-750.
  34. Mathieu C, Zinman B, Hemmingsson JU, Woo V, Colman P, et al. (2016) Efficacy and Safety of Liraglutide Added to Insulin Treatment in Type 1 Diabetes: The ADJUNCT ONE Treat-To-Target Randomized Trial. Diabetes care.
  35. Ahren B, Hirsch IB, Pieber TR, Mathieu C, Gomez- Peralta F, et al. (2016) Efficacy and Safety of Liraglutide Added to Capped Insulin Treatment in Subjects With Type 1 Diabetes: The ADJUNCT TWO Randomized Trial. Diabetes care.
  36. Weinstock RS, Xing D, Maahs DM, Michels A, Rickels MR, et al. (2013) Severe hypoglycemia and diabetic ketoacidosis in adults with type 1 diabetes: results from the T1D Exchange clinic registry. The Journal of clinical endocrinology and metabolism 98(8): 3411- 3419.
  37. Hao W, Gitelman S, DiMeglio LA, Boulware D, Greenbaum CJ, et al. (2016) Fall in C-Peptide during First 4 Years from Diagnosis of Type 1 Diabetes: Variable Relation to Age, HbA1c, and Insulin Dose. Diabetes care.
  38. Renukuntla VS, Ramchandani N, Trast J, Cantwell M, Heptulla RA (2014) Role of Glucagon-Like Peptide-1 Analogue Versus Amylin as an Adjuvant Therapy in Type 1 Diabetes in a Closed Loop Setting With ePID Algorithm. Journal of Diabetes Science and Technology2014; 8(5): 1011-1017.
  39. Ilkowitz JT, Katikaneni R, Cantwell M, Ramchandani N, Heptulla RA (2016) Adjuvant Liraglutide and Insulin Versus Insulin Monotherapy in the Closed- Loop System in Type 1 Diabetes: A Randomized Open-Labeled Crossover Design Trial. Journal of Diabetes Science and Technology 10(5): 1108-1114.
  40. Mudaliar S, Armstrong DA, Mavian AA, O'Connor- Semmes R, Mydlow PK, et al. (2012) Remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2, improves serum glucose profiles in type 1 diabetes. Diabetes care 35(11): 2198-2200.
  41. Perkins BA, Cherney DZ, Partridge H, Soleymanlou N, Tschirhart H, et al. (2014) Sodium-glucose cotransporter 2 inhibition and glycemic control in type 1 diabetes: results of an 8-week open-label proof-of-concept trial. Diabetes care 37(5): 1480- 1483.
  42. Pieber TR, Famulla S, Eilbracht J, Cescutti J, Soleymanlou N, et al. (2015) Empagliflozin as adjunct to insulin in patients with type 1 diabetes: a 4-week, randomized, placebo-controlled trial (EASE-1). Diabetes Obes Metab 17(10): 928-935.
  43. Henry RR, Rosenstock J, Edelman S, Mudaliar S, Chalamandaris AG, et al. (2015) Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: a randomized, double-blind, placebo- controlled pilot study. Diabetes care 38(3): 412-419.
  44. Henry RR, Thakkar P, Tong C, Polidori D, Alba M (2015) Efficacy and Safety of Canagliflozin, a Sodium- Glucose Cotransporter 2 Inhibitor, as Add-on to Insulin in Patients with Type 1 Diabetes. Diabetes care 38(12): 2258-2265.
  45. Sands AT, Zambrowicz BP, Rosenstock J, Lapuerta P, Bode BW, et al. (2015) Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 Diabetes. Diabetes care 38(7): 1181-1188.
  46. Peters AL, Buschur EO, Buse JB, Cohan P, Diner JC, et al. (2015) Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium- Glucose Cotransporter 2 Inhibition. Diabetes care 38(9): 1687-1693.
  47. Kuhadiya ND, Ghanim H, Mehta A, Garg M, Khan S, et al. (2016) Dapagliflozin as Additional Treatment to Liraglutide and Insulin in Patients With Type 1 Diabetes. The Journal of clinical endocrinology and metabolism 101(9): 3506-3515.
  48. Garg M, Kuhadiya ND, Ghanim H, Abuaysheh S BM, Makdissi A, et al. (2016) Liraglutide Acutely Inhibits Glucagon, Lipolysis and Ketogenesis in Type 1 Diabetes. Endocrine Society Annual Meeting.
  49. Ferrannini E, Muscelli E, Frascerra S, Baldi S, Mari A, et al. (2014) Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. The Journal of clinical investigation 124(2): 499-508.
  50. Liljenquist JE, Bomboy JD, Lewis SB, Sinclair-Smith BC, Felts PW, et al. (1974) Effects of glucagon on lipolysis and ketogenesis in normal and diabetic men. The Journal of clinical investigation 53(1): 190-197.
More from this journal

Cite this article

BibTeX
APA
RIS
@article{nitesh2016,
  title   = {Recent Technological and Pharmacological Advances in Type 1 Diabetes},
  author  = {Nitesh D Kuhadiya},
  journal = {Diabetes & Obesity International Journal},
  year    = {2016},
  volume  = {1},
  number  = {2},
  doi     = {10.23880/doij-16000122}
}
Nitesh D Kuhadiya (2016). Recent Technological and Pharmacological Advances in Type 1 Diabetes. Diabetes & Obesity International Journal, 1(2). https://doi.org/10.23880/doij-16000122
TY  - JOUR
TI  - Recent Technological and Pharmacological Advances in Type 1 Diabetes
AU  - Nitesh D Kuhadiya
JO  - Diabetes & Obesity International Journal
PY  - 2016
VL  - 1
IS  - 2
DO  - 10.23880/doij-16000122
ER  -